Stock Watch: AstraZeneca And Clovis Diverge In Oncology Sales Recovery
Sales And Marketing Spending Correlates With Revenue Performance
AstraZeneca’s controversial switch to for-profit COVID-19 vaccine pricing and the costs of the Alexion acquisition clouded its strength in oncology. Meanwhile, Clovis's tight grip on its marketing purse strings may have hit revenue recovery.
